Pharmaceutical Product Positioning

Example Project: Investigate a Pharmaceutical Product's Efficacy

We were involved in a project investigating whether a pharmaceutical product for diabetes treatment resulted in liver toxicity. We were asked to review medical claims data from millions of patients, isolate diabetic patients taking one of several types of diabetes products, and determine whether outcomes for patients on one diabetes product were different than for patients on other diabetes products. We developed an appropriate methodology and the patient outcome measures.

Experience

• Partnered with many of the leading pharmaceutical manufacturers and supported clinical trial Phase 3 work efforts and Phase 4 pharmacoeconomic research, including the following manufacturers--Bristol-Myers Squibb, Wyeth Ayerst, SmithKline Beecham, AstraZeneca, GlaxoWellcome, Eli Lilly, Warner Lambert, and Johnson and Johnson.

• Performed pioneering work in pharmacoeconomic research to define patient outcome measures using medical claims data, including the following--early termination of product use, monotherapy versus combination therapy, drug switching, drug titration, and adverse medical side effects (e.g., gastrointestinal events, renal events).

• Developed a patented system that integrates all inpatient, outpatient, ambulatory, and prescription drug claims data into episodes of care by medical condition (Cave et al, Patent Number 5,970,463). The system was designed to perform pharmacoeconomic research.

• Obtained from the University of California, Los Angeles, a Ph.D. in Health Planning and Policy, and a Masters in Public Health in infectious disease epidemiology--providing a strong clinical, statistical, and methodological background.

Represented Industries and Organizations

Select Topic Public Speaking

Association of Health Services Research and the Foundation for Health Services Research, Implications for Policy, Management, and Clinical Practice. June/July 1991. Controlling the Costs of Ill Health: Employer Strategies and Their Effectiveness.

Novo Nordisk Pharmaceuticals Inc, Diabetes Disease-Management Programs, Coppenhagen, Denmark. September 1994. Capitation Modeling Using the Total Episodes-of-Care Approach.

Novo Nordisk Pharmaceuticals Inc, Diabetes Disease-Management Programs, Phoenix, Arizona. September 1994. Pattern-of-Treatment Monitoring for Disease-Management Programs.

Boots Pharmaceuticals, Thyroid Disease-Management Programs, Lincolnshire, Illinois. January 1995. Developing Global Patterns of Treatment Using the Diagnostic Cluster Approach.

Managed Care Communications/Glaxo Inc, The Essential Guide to Pharmacy Benefits, Tucson, Arizona. February 1995. A View From the Experts.

International Business Communications/Infoline, Clinical Practice Guidelines and Critical Pathways, San Diego, California. April 1995. Using the Diagnostic Cluster Approach to Develop an Effective Continuous Quality Improvement Program.

Pharmaceutical Management Science Association (PMSA), Managed Care and Outcomes Research, San Antonio, Texas. May 1995. Disease Management and Pharmaceutical Capitation Contracts.

Bristol-Myers Squibb/Emron, National Congress: Depression in the 21st Century--A Window to the Future, Washington, D.C. May 1995. Employers' Involvement in Depression and Other Mental Health Management.

Express Scripts, Inc., Outcomes Conference 1997, St. Louis, Missouri. June 1997. Global Trends in Health Care Delivery: Measuring Patient Outcomes.

Glaxo Wellcome, Inc., COPD Managed Care Consultant Advisory Meeting, Dallas, Texas. May 1998. COPD Practice Patterns.

Parke-Davis, Healthcare Management 1999 Horizons National Customer Forum, Phoenix, Arizona. October 1999. Outcomes as a Business Strategy.

Select Topic Articles

Cave, Douglas G. 1994. Impact of Prescription Care Service and Mail Order Drug Programs on Employers' Prescription Drug Costs. Benefits Quarterly 10(4), pp. 21-30.

Cave, Douglas G., Susan M. Barrow, Robert P. Navarro, and Kristin Arrandale. 1996. Integrating Medical and Drug Claims Data. PharmaCare Economics 1(1), pp. 30-38.

Baker, Trish, Alan Ertle, and Douglas G. Cave. 1997. Challenges to Identifying Actual Diabetes Case-Mix Complexity and Total Treatment Charges. Medical Interface 10(4), pp. 91-96.

Arrandale, Kristin E., Paul R. Wilson, and Douglas G. Cave. 1997. Medical Trends Report: Low Back Pain. Medical Interface 10(8), pp. 60-62.

Ertle, Alan, Robert Navarro, and Douglas G. Cave. 1997. Medical Trends Report: Asthma. Managed Care Interface 10(9), pp. 80-82.

Arrandale, Kristin E., Robert P. Navarro, and Douglas G. Cave. 1998. Hypertension. Managed Care Interface 11(1), pp. 50-52.

Cave, Douglas G. 1998. The PPS/Formulary Monitor. St. Louis, Missouri. Practice Patterns Science.

Terry, Christine M., Stephen Thomas and Douglas G. Cave. Medical Trends Report: "Major Depression." Managed Care Interface 1998; 11(11), pp. 58-60.

Sutor, Susan M., Joseph A. Gricar, and Douglas G. Cave. Medical Trends Report: "Rheumatoid Arthritis." Managed Care Interface 1999; 12 (6), pp. 51-53.

Monajati, Susan D., Jim Clement, and Douglas G. Cave. Medical Trends Report: "Low Back Pain." Managed Care Interface 1999; 12 (8): 52-54.

Copyright © 2003 Cave Consulting Group, All Rights Reserved